Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer

Journal of Thyroid Research

Volumn 2011, Issue , 2011, Pages

  Cabanillas, Maria E ^a   Hu, Mimi I ^a   Durand, Jean Bernard ^a   Busaidy, Naifa L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLARITHROMYCIN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFAVIRENZ; ERYTHROMYCIN; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; ITRACONAZOLE; NELFINAVIR; NEVIRAPINE; PAZOPANIB; PHENOBARBITAL; PHENYTOIN; PIOGLITAZONE; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SORAFENIB; SUNITINIB; VANDETANIB; VERAPAMIL; VORICONAZOLE;

ABDOMINAL DISCOMFORT; ACUTE PANCREATITIS; ADL DISABILITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIHYPERTENSIVE THERAPY; ARTERIAL THROMBOEMBOLISM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BRAIN HEMORRHAGE; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DESQUAMATION; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DYSESTHESIA; DYSGEUSIA; EPISTAXIS; ERYTHEMA; FATIGUE; FOOT PAIN; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HAND PAIN; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KERATOACANTHOMA; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG HEMORRHAGE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PAINLESS SWELLING; PARESTHESIA; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; REVIEW; SIDE EFFECT; SKIN TINGLING; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; STOMATITIS; SWELLING; THROMBOCYTOPENIA; THYROID CANCER; THYROTROPIN BLOOD LEVEL; TORSADE DES POINTES; ULCER; VAGINA BLEEDING; WEIGHT REDUCTION;

EID: 84861778428     PISSN: 20908067     EISSN: 20420072     Source Type: Journal    
DOI: 10.4061/2011/985780     Document Type: Review

References (47)

1. American Cancer Society, Cancer Facts and Figures, American Cancer Society, 2010.
2. K. C. Bible, V. J. Suman, J. R. Molina et al., "Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study", The Lancet Oncology, vol. 11, no. 10, pp. 962-972, 2010.
3. L. L. Carr, D. A. Mankoff, B. H. Goulart et al., "Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation", Clinical Cancer Research, vol. 16, no. 21, pp. 5260-5268, 2010.
4. R. T. Kloos, M. D. Ringel, M. V. Knopp et al., "Phase II trial of sorafenib in metastatic thyroid cancer", Journal of Clinical Oncology, vol. 27, no. 10, pp. 1675-1684, 2009.
5. S. A. Wells, B. G. Robinson, R. F. Gagel et al., "Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA)", Journal of Clinical Oncology, vol. 28, supplement, 2010.
6. E. T. Lam, M. D. Ringel, R. T. Kloos et al., "Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer", Journal of Clinical Oncology, vol. 28, no. 14, pp. 2323-2330, 2010.
7. J. A. De Souza, N. Busaidy, A. Zimrin et al., "Phase II trial of sunitinib in medullary thyroid cancer (MTC)", Journal of Clinical Oncology, vol. 28, supplement, 2010.
8. Package insert sorafenib (Nexavar). In: Bayer HealthCare and Onyx Pharmaceuticals.
9. Package insert vandetanib (Vandetanib). In: AstraZeneca Pharmaceuticals.
10. R. J. Johnson, S. D. Kivlighn, Y. G. Kim, S. Suga, and A. B. Fogo, "Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease", American Journal of Kidney Diseases, vol. 33, no. 2, pp. 225-234, 1999. (Pubitemid 29072223)
11. D. C. Sane, L. Anton, and K. B. Brosnihan, "Angiogenic growth factors and hypertension", Angiogenesis, vol. 7, no. 3, pp. 193-201, 2004.
12. M. Schmidinger, D. Arnold, C. Szczylik, J. Wagstaff, and A. Ravaud, "Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice", Cancer Investigation, vol. 28, no. 8, pp. 856-864, 2010.
13. M. L. Veronese, A. Mosenkis, K. T. Flaherty et al., "Mechanisms of hypertension associated with BAY 43-9006", Journal of Clinical Oncology, vol. 24, no. 9, pp. 1363-1369, 2006. (Pubitemid 46621999)
14. H. A. J. Struijker Boudier, J. L. M. L. Le Noble, M. W. J. Messing, M. S. P. Huijberts, F. A. C. Le Noble, and H. Van Essen, "The microcirculation and hypertension", Journal of Hypertension, vol. 10, no. 7, supplement, pp. S147-S156, 1992. (Pubitemid 23045181)
15. B. I. Rini, D. P. Cohen, D. R. Lu et al., "Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib", Journal of the National Cancer Institute, vol. 103, no. 9, pp. 763-773, 2011.
16. M. L. Maitland, G. L. Bakris, H. R. Black et al., "Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors", Journal of the National Cancer Institute, vol. 102, no. 9, pp. 596-604, 2010.
17. S. Mallick, R. Kanthety, and M. Rahman, "Home blood pressure monitoring in clinical practice: a review", American Journal of Medicine, vol. 122, no. 9, pp. 803-810, 2009.
18. Package insert sunitinib (Sutent). In: Pfizer Labs.
19. Package insert pazopanib (Votrient). In: GlaxoSmithKline.
20. A. Y. Khakoo, C. M. Kassiotis, N. Tannir et al., "Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor", Cancer, vol. 112, no. 11, pp. 2500-2508, 2008.
21. T. F. Chu, M. A. Rupnick, R. Kerkela et al., "Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib", The Lancet, vol. 370, no. 9604, pp. 2011-2019, 2007. (Pubitemid 350236338)
22. V. Chintalgattu, D. Ai, R. R. Langley et al., "Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress", Journal of Clinical Investigation, vol. 120, no. 2, pp. 472-484, 2010.
23. X. Zhu, S. Wu, W. L. Dahut, and C. R. Parikh, "Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis", American Journal of Kidney Diseases, vol. 49, no. 2, pp. 186-193, 2007. (Pubitemid 46178407)
24. T. V. Patel, J. A. Morgan, G. D. Demetri et al., "A preeclampsialike syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib", Journal of the National Cancer Institute, vol. 100, no. 4, pp. 282-284, 2008. (Pubitemid 351480534)
25. C. Frangié, C. Lefaucheur, J. Medioni, C. Jacquot, G. S. Hill, and D. Nochy, "Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma", The Lancet Oncology, vol. 8, no. 2, pp. 177-178, 2007. (Pubitemid 46158384)
26. S. K. Winn, S. Ellis, P. Savage, S. Sampson, and J. E. Marsh, "Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?" Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 673-675, 2009.
27. V. Eremina, M. Sood, J. Haigh et al., "Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases", Journal of Clinical Investigation, vol. 111, no. 5, pp. 707-716, 2003. (Pubitemid 36278589)
28. C. N. Sternberg, I. D. Davis, J. Mardiak et al., "Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial", Journal of Clinical Oncology, vol. 28, no. 6, pp. 1061-1068, 2010.
29. B. Escudier, T. Eisen, W. M. Stadler et al., "Sorafenib in advanced clear-cell renal-cell carcinoma", New England Journal of Medicine, vol. 356, no. 2, pp. 125-134, 2007. (Pubitemid 46089673)
30. R. J. Motzer, T. E. Hutson, P. Tomczak et al., "Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma", Journal of Clinical Oncology, vol. 27, no. 22, pp. 3584-3590, 2009.
31. F. A. B. Schutz, T. K. Choueiri, and C. N. Sternberg, "Pazopanib: clinical development of a potent anti-angiogenic drug", Critical Reviews in Oncology/Hematology, vol. 77, no. 3, pp. 163-171, 2011.
32. C. Robert, J. P. Arnault, and C. Mateus, "RAF inhibition and induction of cutaneous squamous cell carcinoma", Current Opinion in Oncology, vol. 23, no. 2, pp. 177-182, 2011.
33. M. E. Lacouture, A. Desai, K. Soltani et al., "Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor", Clinical and Experimental Dermatology, vol. 31, no. 6, pp. 783-785, 2006. (Pubitemid 44563396)
34. D. S. Hong, S. B. Reddy, V. G. Prieto et al., "Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib", Archives of Dermatology, vol. 144, no. 6, pp. 779-782, 2008. (Pubitemid 351846880)
35. J. P. Arnault, J. Wechsler, B. Escudier et al., "Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib", Journal of Clinical Oncology, vol. 27, no. 23, pp. e59-e61, 2009.
36. T. Kamba and D. M. McDonald, "Mechanisms of adverse effects of anti-VEGF therapy for cancer", British Journal of Cancer, vol. 96, no. 12, pp. 1788-1795, 2007. (Pubitemid 46912024)
37. C. F. Xu, B. H. Reck, Z. Xue et al., "Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism", British Journal of Cancer, vol. 102, no. 9, pp. 1371-1377, 2010.
38. H. Minami, K. Kawada, H. Ebi et al., "Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors", Cancer Science, vol. 99, no. 7, pp. 1492-1498, 2008. (Pubitemid 351761743)
39. J. L. Spivak, "Polycythemia vera: myths, mechanisms, and management", Blood, vol. 100, no. 13, pp. 4272-4290, 2002. (Pubitemid 35429665)
40. B. Y. Y. Tam, K. Wei, J. S. Rudge et al., "VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis", Nature Medicine, vol. 12, no. 7, pp. 793-800, 2006. (Pubitemid 44050069)
41. E. Wong, L. S. Rosen, M. Mulay et al., "Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity", Thyroid, vol. 17, no. 4, pp. 351-355, 2007. (Pubitemid 46776140)
42. M. E. Cabanillas, S. G. Waguespack, Y. Bronstein et al., "Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2588-2595, 2010.
43. E. R. Plimack, N. Tannir, E. Lin, B. N. Bekele, and E. Jonasch, "Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon", Cancer, vol. 115, no. 9, pp. 1859-1866, 2009.
44. K. Kim, K. Flaherty, P. Champman et al., "Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM)", Journal of Clinical Oncology, vol. 29, supplement, 2011.
45. J. A. Gottlieb and C. S. Hill Jr., "Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients", New England Journal of Medicine, vol. 290, no. 4, pp. 193-197, 1974.
46. K. Zimmermann, A. Schmittel, U. Steiner et al., "Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib", Oncology, vol. 76, no. 5, pp. 350-354, 2009.
47. A. Fernández, A. Sanguino, Z. Peng et al., "An anticancer CKit kinase inhibitor is reengineered to make it more active and less cardiotoxic", Journal of Clinical Investigation, vol. 117, no. 12, pp. 4044-4054, 2007. (Pubitemid 350224113)